Literature DB >> 16845517

Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.

Kiminori Sato1.   

Abstract

Laryngopharyngeal reflux disease (LPRD) with nocturnal recovery of gastric acid secretion (nocturnal acid breakthrough: NAB) with proton pump inhibitors (PPI) was first reported. A 79-year-old Japanese woman complained of globus pharyngeus and mild heartburn was examined with the use of tetra-probe 24-h pH monitoring. She had been treated for reflux esophagitis (GERD) for 12 months prior to her visit to our office. She took Lansoprazole (30 mg/day) before dinner every day. The tetra-probe 24-h pH monitoring revealed that the recovery of gastric acid secretion occurred 6.5 h after taking the dose of PPI. The intragastric pH dropped < 4 at about 23:00 and remained below that level for 4 h and 50 min. The 24-h pH-metry at each probe showed that the nocturnal recovery of gastric acid secretion with PPI (NAB on PPI) influenced gastroesophageal and laryngopharyngeal refluxes. The symptoms of the pharynx and esophagus disappeared after taking H2 receptor antagonist (H2RA) additionally before bedtime.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845517     DOI: 10.1007/s00405-006-0117-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  8 in total

1.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.

Authors:  K Adachi; T Katsube; A Kawamura; T Takashima; M Yuki; K Amano; S Ishihara; R Fukuda; M Watanabe; Y Kinoshita
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

2.  Laryngopharyngeal reflux: consensus conference report.

Authors:  J Koufman; R T Sataloff; R Toohill
Journal:  J Voice       Date:  1996-09       Impact factor: 2.009

Review 3.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Authors:  T Ishizaki; Y Horai
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

4.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

Authors:  N Shirai; T Furuta; Y Moriyama; H Okochi; K Kobayashi; M Takashima; F Xiao; K Kosuge; K Nakagawa; H Hanai; K Chiba; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

5.  Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.

Authors:  William K Fackler; Tina M Ours; Michael F Vaezi; Joel E Richter
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

6.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.

Authors:  P L Peghini; P O Katz; N A Bracy; D O Castell
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

7.  Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.

Authors:  Kyoichi Adachi; Yoshinori Komazawa; Hirofumi Fujishiro; Takafumi Mihara; Masahiro Ono; Mika Yuki; Akira Kawamura; Mohammad Azharul Karim Rumi; Yuji Amano; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

8.  Gastroesophageal reflux laryngitis resistant to omeprazole therapy.

Authors:  I D Bough; R T Sataloff; D O Castell; J R Hills; R M Gideon; J R Spiegel
Journal:  J Voice       Date:  1995-06       Impact factor: 2.009

  8 in total
  1 in total

Review 1.  Gastroesophageal reflux/laryngopharyngeal reflux disease: a critical analysis of the literature.

Authors:  M N Kotby; O Hassan; Aly M N El-Makhzangy; M Farahat; P Milad
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.